Why the study?
Evidence on the efficacy, safety, pharmacokinetics, and pharmacodynamics of therapeutic-dose rivaroxaban in patients undergoing bariatric surgery remains limited.
Does bariatric surgery alter the pharmacokinetic and pharmacodynamic parameters of therapeutic-dose rivaroxaban (20 mg) in patients with BMI >= 35 kg/m2 during the first 3 months postoperatively?
Does bariatric surgery alter the pharmacokinetic and pharmacodynamic parameters of therapeutic-dose rivaroxaban (20 mg) in patients with BMI >= 35 kg/m2 during the first 3 months postoperatively?
In a small exploratory cohort, therapeutic-dose rivaroxaban (20 mg) pharmacokinetic exposure and pharmacodynamic activity remained comparable to presurgical baseline levels during the first three months after bariatric surgery.
Answers are grounded in this paper and cite their sources.
May alter rivaroxaban exposure post-bariatric surgery; leaves open optimal dosing for VTE prevention in this population.
Background/Objectives: Direct oral anticoagulants (DOAC) are widely used for the prevention and treatment of venous thromboembolism (VTE) in the general population. However, evidence on their efficacy and safety in patients undergoing bariatric surgery remains limited. The objective of this study was to investigate the effect of bariatric surgery on the pharmacokinetic (PK) and pharmacodynamic (PD) parameters of therapeutic-dose rivaroxaban. Methods: This single-centre clinical study retrospectively analysed PK/PD data from patients with a body mass index (BMI) ≥ 35 kg/m2 receiving extended anticoagulation with 20 mg rivaroxaban. Rivaroxaban PK (plasma concentrations) and PD (prothrombin fragments F1 + 2 and D-dimers) parameters were repeatedly measured prior to and up to 3 months after bariatric surgery. Results: Nine patients (mean age 50 years, 78% female) with a mean BMI of 46.8 kg/m2 were included; seven patients underwent sleeve gastrectomy and two underwent Roux-en-Y gastric bypass surgery. The geometric mean rivaroxaban areas under the curve (AUC) before, and at 3 days, 30 days, and 3 months after bariatric surgery were 2441.8 µg·h/L (geometric coefficient of variation (GCV) 1.44, n = 7), 2474.7 µg·h/L (GCV 1.41, n = 9), 2468.2 µg·h/L (GCV 1.74, n = 8), and 3266.4 µg·h/L (GCV 1.25, n = 6), respectively. Prothrombin fragments F1+2 showed a time-dependent decrease after rivaroxaban administration during the early postoperative period, comparable to that observed in the presurgical measurements. Mean D-dimer levels were increased immediately after bariatric surgery (consistent with a surgery-related increase), but were comparable to the presurgical measurement at later time points. Conclusions: Based on the limited PK/PD data, rivaroxaban exposure, as assessed by AUC, remained comparable to presurgical values during the first three months after bariatric surgery. These findings are exploratory and require confirmation in larger prospective studies.
No takes yet. Share an insight, caveat, or question.
Stirnimann et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: